Cytomegalovirus Infections Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Epidemiology, Medication, NDA Approvals, Pipeline, Therapeutics and Companies by DelveInsight

Cytomegalovirus infections companies working in the market are ModernaTX, Inc., Merck Sharp & Dohme LLC, GlaxoSmithKline, AlloVir, and others.
(Albany, USA) DelveInsight's Cytomegalovirus Infections Market Insights report includes a comprehensive understanding of current treatment practices, CMV infections emerging drugs, market share of individual therapies, and current and forecasted CMV infections market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

The cytomegalovirus infections market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted cytomegalovirus infections market size from 2020 to 2034, segmented by seven major markets. The cytomegalovirus infections Market Report also covers current cytomegalovirus infections treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the cytomegalovirus infections market.

Request for sample report @ Cytomegalovirus Infections Market Size [https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Key Takeaways from the Cytomegalovirus Infections Market Report

* According to DelveInsight's analysis, the cytomegalovirus infections market size across the 7MM is expected to grow with a significant CAGR by 2034.
* DelveInsight's analysis reveals that the overall diagnosed population of cytomegalovirus infections in the 7MM was reported as 111K in 2022.
* Prominent companies working in the domain of cytomegalovirus infections, including ModernaTX, Inc., Merck Sharp & Dohme LLC, GlaxoSmithKline, AlloVir, and others, are actively working on innovative drugs for cytomegalovirus infections. These novel cytomegalovirus infections therapies are anticipated to enter the cytomegalovirus infections market in the forecast period and are expected to change the market.
* Some of the key therapies for cytomegalovirus infections treatment include mRNA-1647, Letermovir 480 MG [Prevymis], Pentamer (low)/gB(low)/Adjuvant vaccine, Posoleucel (ALVR105), and others.
* In February 2025, Takeda announced results of an Open-label, Single-arm Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Maribavir in Chinese Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Cidofovir or Foscarnet
* In December 2024, ModernaTX, Inc announced results of a Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
* In June 2024, SymBio Pharmaceuticals announced results of a Phase IIa, Open-label, Multiple Ascending Dose Confirmation Study of the Safety and Tolerability of Intravenous Administration of Brincidofovir in Subjects With Adenovirus Infection or Cytomegalovirus Infection
* In February 2024, A novel mRNA vaccine currently undergoing phase 3 clinical trials demonstrates superior efficacy in stimulating the immune system to combat cytomegalovirus infection. This experimental mRNA vaccine targeting human cytomegalovirus (CMV), a prevalent virus with potential prenatal transmission, has elicited highly encouraging immune responses compared to other CMV vaccine candidates, as per research conducted by investigators from Weill Cornell Medicine.

Discover which therapies are expected to grab the cytomegalovirus infections market share @ Cytomegalovirus Infections Treatment Market Report [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Cytomegalovirus Infections Overview

Cytomegalovirus (CMV) infections, classified as herpesvirus type 5, exhibit a broad spectrum of symptoms ranging from asymptomatic cases to manifestations such as fever and fatigue, reminiscent of infectious mononucleosis, and severe conditions affecting organs like the eyes, brain, or other internal organs. While prevalent across all age groups, a robust immune system in healthy individuals typically prevents the virus from causing illness. Blood tests indicate that a substantial percentage, ranging from 60 to 90%, of adults have experienced a CMV Infections infection at some point.

Following infection, CMV infections can either prompt immediate symptoms or remain inactive in different tissues throughout a person's life. Dormant CMV infections may be reactivated by various triggers, leading to viral replication that can occasionally result in disease. The infection may affect organs such as the lungs, gastrointestinal tract, brain, spinal cord, or eyes. In infants, the typical method for diagnosing the condition involves sending a urine sample to a laboratory to cultivate and identify the virus. Additionally, blood tests capable of detecting antibodies to CMV can validate a recent infection. However, it's important to note that these tests cannot ascertain the presence of the disease itself.

Cytomegalovirus Infections Epidemiology Segmentation

The cytomegalovirus infections epidemiology section provides insights into the historical and current CMV infections patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The CMV infections market report proffers epidemiological analysis for the study period 2020- 2034 in the 7MM segmented into:

* Total Cytomegalovirus Infections Diagnosed Cases
* Number of Infants Born with Congenital CMV
* CMV Retinitis among HIV Patients
* CMV Patients among Hematopoietic Stem Cell Transplants (HSCT)
* Number of CMV Patients among SOT
* Number of Refractory CMV Patients after HSCT/SOT

Download the report to understand which factors are driving cytomegalovirus infections epidemiology trends @ Cytomegalovirus Infections Prevalence [https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Cytomegalovirus Infections Treatment Market

The CMV treatment market is categorized into Prophylactic Drugs and Therapeutic Drugs. Preventing the transmission of cytomegalovirus is crucial, especially since it is commonly spread through infected bodily fluids that can be absorbed through the nose or mouth of a susceptible person. Two primary strategies for preventing CMV disease after liver transplantation are preemptive therapy and antiviral prophylaxis. In preemptive therapy, patients undergo monitoring for evidence of CMV replication using sensitive assays, typically quantitative nucleic acid amplification tests like PCR or, less commonly, detection of pp65 antigenemia. When asymptomatic CMV replication is detected, preemptive antiviral therapy is administered to prevent progression to symptomatic clinical disease.

In the United States, antiviral medications are employed to address CMV infection subsequent to transplant procedures. These medications encompass valganciclovir, ganciclovir, cidofovir, foscarnet, or a combination thereof. Prevymis (Letermovir) has received approval from the FDA for preventing Human Cytomegalovirus (HCMV) infection in transplant recipients. Letermovir is an authorized anti-CMV drug, with FDA approval in November 2017 and EMA marketing authorization in January 2018.

Letermovir operates by inhibiting the viral terminase complex, composed of CMV-encoded proteins pUL51, pUL56, and pUL89, crucial for forming DNA-containing viral capsids. This drug is administered either orally or through intravenous infusion. It has been sanctioned for prophylactic use against CMV in allogeneic hematopoietic-cell transplantation patients undergoing immunosuppressive therapy.

Learn more about the FDA-approved drugs for cytomegalovirus infections @ Drugs for Cytomegalovirus Infections Treatment [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Key Cytomegalovirus Infections Therapies and Companies

* mRNA-1647: ModernaTX, Inc.
* Letermovir 480 MG [Prevymis]: Merck Sharp & Dohme LLC
* Pentamer (low)/gB(low)/Adjuvant vaccine: GlaxoSmithKline
* Posoleucel (ALVR105): AlloVir

Cytomegalovirus Infections Market Dynamics

The cytomegalovirus infections market dynamics are anticipated to change in the coming years. Growing research and development is increasing the demand for better diagnosis and treatment options for cytomegalovirus infection, and the increased public awareness creates a lucrative opportunity for the innovation of therapeutics to drive the CMV market. However, the therapies currently approved for CMV have many side effects; thus, the development of a novel mechanism of action with less toxicity could capture a large CMV infection market.

Furthermore, many potential therapies are being investigated for the treatment of cytomegalovirus infections, and it is safe to predict that the treatment space will significantly impact the cytomegalovirus infections market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the cytomegalovirus infections market in the 7MM.

However, several factors may impede the growth of the cytomegalovirus infections market. To enhance the prognosis of CMV and improve outcomes for patients, there is a pressing need for expanded diagnostic options. Existing diagnostic methods fall short in detecting certain features of congenital CMV, underscoring gaps in our current understanding. The intricate mechanism of action of the disease, with multiple targets for inhibition, remains insufficiently explored. Furthermore, nearly all drugs for CMV infection have lost patent protection, leaving only one exempt. The availability of generic drugs is poised to impact the overall sales of the CMV market.

Moreover, cytomegalovirus infections treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the cytomegalovirus infections market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the cytomegalovirus infections market growth.

Scope of the Cytomegalovirus Infections Market Report

* Study Period: 2020- 2034
* Cytomegalovirus Infections Report Coverage: 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
* Key Cytomegalovirus Infections Companies: ModernaTX, Inc., Merck Sharp & Dohme LLC, GlaxoSmithKline, AlloVir, and others
* Key Cytomegalovirus Infections Therapies: mRNA-1647, Letermovir 480 MG [Prevymis], Pentamer (low)/gB(low)/Adjuvant vaccine, Posoleucel (ALVR105), and others

* Cytomegalovirus Infections Therapeutic Assessment: Cytomegalovirus Infections current marketed and emerging therapies
* Cytomegalovirus Infections Market Dynamics: Attribute Analysis of Emerging Cytomegalovirus Infections Drugs
* Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Unmet Needs, KOL's views, Analyst's views, Cytomegalovirus Infections Market Access and Reimbursement

Discover more about cytomegalovirus infections drugs in development @ Cytomegalovirus Infections Clinical Trials [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Cytomegalovirus Infections Market Key Insights

2. Cytomegalovirus Infections Market Report Introduction

3. Cytomegalovirus Infections Market Overview at a Glance

4. Cytomegalovirus Infections Market Executive Summary

5. Disease Background and Overview

6. Cytomegalovirus Infections Treatment and Management

7. Cytomegalovirus Infections Epidemiology and Patient Population

8. Patient Journey

9. Cytomegalovirus Infections Marketed Drugs

10. Cytomegalovirus Infections Emerging Drugs

11. Seven Major Cytomegalovirus Infections Market Analysis

12. Cytomegalovirus Infections Market Outlook

13. Potential of Current and Emerging Therapies

14. KOL Views

15. Unmet Needs

16. SWOT Analysis

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cytomegalovirus-infections-treatment-market-2034-ema-pdma-fda-approvals-clinical-trials-epidemiology-medication-nda-approvals-pipeline-therapeutics-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.